Want to see DE:HPHA full AI Analyst Report?

Heidelberg Pharma AG (HPHA) Price & Analysis

5 Followers

HPHA Stock Chart & Stats

€2.62

€0.02(0.83%)

At close: Jan 08 4:00 PM EST

€2.62

€0.02(0.83%)

Day’s Range― - ―

52-Week Range€2.20 - €3.34

Previous CloseN/A

Volume3.96K

Average Volume (3M)4.34K

Market Cap

€105.26M

Enterprise Value€152.89M

Total Cash (Recent Filing)€24.93M

Total Debt (Recent Filing)€45.98K

Price to Earnings (P/E)―

Beta0.82

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding46,784,317

10 Day Avg. Volume8,516

30 Day Avg. Volume4,336

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)-12.31

Price to Sales (P/S)92.22

P/FCF Ratio-4.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

ATAC Oncology PlatformThe ATAC platform gives Heidelberg Pharma a focused technology foundation in oncology, using targeted antibodies to deliver amanitin to tumor cells. Internal and partnered programs create multiple development paths and could support durable value if the platform produces clinically and commercially viable therapies.

Revenue ReboundThe sharp TTM revenue rebound indicates stronger recent commercial or partnership-related activity than in the prior period. Although it has not yet produced profitability, sustained revenue expansion would improve operating leverage and provide a broader base from which the company can fund its oncology pipeline.

Low Stated DebtMinimal stated debt reduces the burden of scheduled interest and principal payments relative to a highly leveraged biotechnology balance sheet. This provides some financial flexibility as Heidelberg Pharma develops its programs, even though negative equity and cash burn remain important constraints.

Bears Say

Persistent UnprofitabilityLarge ongoing losses show that current revenue is not sufficient to cover Heidelberg Pharma’s operating expenses. Persistently negative and highly compressed margins limit internally generated funding, increase reliance on future financing, and make the economics of continued pipeline investment more difficult.

Sustained Cash BurnPersistent operating and free-cash-flow outflows indicate that the business consumes substantial cash while advancing its activities. Worsening TTM free cash flow increases dependence on external capital and may force management to prioritize financing needs over pipeline expansion or other strategic investments.

Negative Shareholders’ EquityNegative equity shows that cumulative losses have eroded the company’s capital base despite minimal stated debt. This weakens financial resilience, reduces flexibility in funding development programs, and elevates the risk that additional capital could be required on terms that dilute existing shareholders.

HPHA FAQ

What was Heidelberg Pharma AG’s price range in the past 12 months?

Heidelberg Pharma AG lowest stock price was €2.20 and its highest was €3.34 in the past 12 months.

What is Heidelberg Pharma AG’s market cap?

Heidelberg Pharma AG’s market cap is €105.26M.

When is Heidelberg Pharma AG’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Heidelberg Pharma AG’s earnings last quarter?

Currently, no data Available

Is Heidelberg Pharma AG overvalued?

According to Wall Street analysts Heidelberg Pharma AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Heidelberg Pharma AG pay dividends?

Heidelberg Pharma AG does not currently pay dividends.

What is Heidelberg Pharma AG’s EPS estimate?

Heidelberg Pharma AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Heidelberg Pharma AG have?

Heidelberg Pharma AG has 46,784,317 shares outstanding.

What happened to Heidelberg Pharma AG’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Heidelberg Pharma AG?

Currently, no hedge funds are holding shares in DE:HPHA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Heidelberg Pharma AG Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

444.89%

Trailing 12-Months

Asset Growth

-24.91%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Heidelberg Pharma AG

Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.